Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02964884 · ClinicalTrials.gov registry record · Phase 2
Interventions for Reading Disabilities in NF1
A Phase 2 study of Neurofibromatosis Type 1 and NF1, sponsored by Vanderbilt University.
- Active
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT02964884 is a Phase 2 study of Neurofibromatosis Type 1 and NF1 that is active but no longer recruiting, run by Vanderbilt University. The registered enrollment target is 120 participants, below the 154-participant average among 17 other Neurofibromatosis Type 1 trials with a reported enrollment target (22% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02964884, a Phase 2 study of Neurofibromatosis Type 1 and NF1, is active but no longer recruiting, sponsored by Vanderbilt University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
Neurofibromatosis Type 1 (NF1) is a common genetic disorder that is associated with a four times greater risk of learning disabilities, including reading disabilities, and a deficiency of neurofibromin - a protein important in a signaling pathway that regulates learning and memory. Our previous work (NS49096) demonstrated that school-age children with NF+RD can respond to standard phonologically-based reading tutoring originally developed to treat reading disability in the general population. Combining our work with that by other researchers suggesting that a medication (Lovastatin) may counteract the effects of the deficient neurofibromin, and possibly ameliorate learning disabilities in NF1, the investigator propose to examine the synergistic effects of medication plus reading tutoring.
Conditions Studied
Interventions
- DRUG Placebo Oral Tablet
- DRUG Lovastatin
- BEHAVIORAL reading tutoring intervention
- BEHAVIORAL Other Academic "sham" tutoring
Study Locations (1)
Tennessee
- Vanderbilt University - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2016-11 |
| Est. Completion | 2027-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02964884
The ClinicalTrials.gov registry entry for NCT02964884 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 154-participant average among 17 other Neurofibromatosis Type 1 trials with a reported enrollment target (22% lower). The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Neurofibromatosis Type 1 appearing as the primary indexed condition, and to 4 interventions - of which Placebo Oral Tablet is the first listed.
NCT02964884 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT02964884 about?
NCT02964884 is a clinical study titled "Interventions for Reading Disabilities in NF1". Neurofibromatosis Type 1 (NF1) is a common genetic disorder that is associated with a four times greater risk of learning disabilities, including reading disabilities, and a deficiency of neurofibromin - a protein important in a signaling pathway that regulates learning and memory. Our previous work...
What is the current status of trial NCT02964884?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2016-11. Estimated completion is 2027-01.
What conditions does trial NCT02964884 study?
This clinical trial studies the following conditions: Neurofibromatosis Type 1, NF1, Reading Disability, Learning Disability.
What interventions are being tested in trial NCT02964884?
The interventions under investigation include: Placebo Oral Tablet (DRUG), Lovastatin (DRUG), reading tutoring intervention (BEHAVIORAL), Other Academic "sham" tutoring (BEHAVIORAL).
Who is sponsoring clinical trial NCT02964884?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02964884 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurofibromatosis Type 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
RECRUITING · Phase 2
-
Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
ACTIVE NOT RECRUITING · Phase 2
-
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors
COMPLETED · Phase 2
-
Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence
RECRUITING · NA
-
Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative Study
RECRUITING
-
A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.